Effect of gefitinib (ZD1839) on metastatic brain tumour
- 31 March 2004
- journal article
- other
- Published by Elsevier in Lung Cancer
- Vol. 43 (3) , 371-372
- https://doi.org/10.1016/j.lungcan.2003.09.017
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancerPublished by Elsevier ,2003
- ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use programLung Cancer, 2003
- Dramatic effect of ZD1839 (‘Iressa’) in a patient with advanced non-small-cell lung cancer and poor performance statusLung Cancer, 2003
- A case study documenting the anticancer activity of ZD1839 (Iressa) in the brainAnnals of Oncology, 2003
- ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I TrialJournal of Clinical Oncology, 2002